{ "docId": "019dd923-5ca1-7489-b639-45501f4b359b", "docSlug": "158df8627a0b9aca", "documentTitle": "Opioid Conflicts Majority Staff Report", "authorId": "McKinsey", "authorName": "U.S. House Committee on Oversight and Reform", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "portrait", "aspectRatio": 0.773, "pageNumber": 14, "pageCount": 53, "prevPage": 13, "nextPage": 15, "slideType": "appendix_disclosure", "function": "other", "density": "overcrowded", "nDataPoints": 0, "notes": "This page appears to be from a legal or investigative report, containing detailed footnotes referencing internal McKinsey documents.", "elementsJson": [ "paragraph", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/14", "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b", "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json", "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-14", "components": [ { "bbox": null, "kind": "callout", "text": "We found a partner colleague, Ted Fuhr, who may be the right person to provide the Teva point of view. He knows the regulatory space and generics players and has negotiated against Teva.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd951-cdec-74db-b49a-d77f6dfe4692", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.075, "w": 0.764, "x": 0.118, "y": 0.43 }, "kind": "paragraph", "text": "Katy George is one of the most senior partners at McKinsey, currently serving as a \"member of the Shareholders Council, the firm's equivalent of the board of directors, and the firm's 15-person global leadership team.\"53 From April 2010 to December 2011, Ms. George worked on eight separate FDA engagements, including two projects helping set up a system to track and trace the safety of dangerous drugs such as opioids.54", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "504b2595-aab4-4cea-a23f-d3917d89ca11", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.105, "w": 0.764, "x": 0.118, "y": 0.158 }, "kind": "paragraph", "text": "In January 2014, Mr. Fuhr worked on a project supporting the FDA's Office of Generic Drugs at a time when Purdue was facing significant competition from a generic opioid produced by Teva Pharmaceuticals after an adverse court ruling on several patents, threatening OxyContin's market share.48 On January 15, 2014, a McKinsey partner emailed other consultants that \"Teva would still need to submit an ANDA [abbreviated new drug application] for a tamper-resistant product and get it approved\" by FDA.49", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "58689ac9-98d1-4365-b5c4-9b72b5fa22f0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.075, "w": 0.764, "x": 0.118, "y": 0.27 }, "kind": "paragraph", "text": "One week later, the same McKinsey consultant emailed a senior executive at Purdue and introduced Mr. Fuhr: \"We found a partner colleague, Ted Fuhr, who may be the right person to provide the Teva point of view. He knows the regulatory space and generics players and has negotiated against Teva.\"50 Mr. Fuhr's project at FDA lasted several more weeks after this email, ending on February 3, 2014.51", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7ae2d2c2-801f-44f1-a4ef-3c1fa4e7e446", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.045, "w": 0.764, "x": 0.118, "y": 0.116 }, "kind": "paragraph", "text": "Safety Plan.46 Eight days later, on May 13, 2010, Mr. Fuhr was invited to a call with other McKinsey consultants to discuss a request from Purdue, for a matter on which he was not staffed.47", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8c5cd5f1-a950-4d6b-a4a7-d21d4ac7c881", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.764, "x": 0.118, "y": 0.355 }, "kind": "paragraph", "text": "After this introduction, Mr. Fuhr was staffed on five official projects at Purdue Pharma spanning from May 2015 to September 2017.52", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "bf2909f4-144f-4548-b131-83938733c9ef", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "We found a partner colleague, Ted Fuhr, who may be the right person to provide the Teva point of view. He knows the regulatory space and generics players and has negotiated against Teva.", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd951-cdec-74db-b49a-db464a2489dd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.764, "x": 0.118, "y": 0.55 }, "kind": "source-note", "text": "46-54 Footnotes detailing document references.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "31f895d4-ed26-4abc-9bae-b4dfc2f6c86f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.118, "y": 0.4 }, "kind": "title", "text": "Katy George", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "37fb7da9-daf2-4e34-91e3-2172ab109cc3", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 28, "from": 6, "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "loops": [ { "to": 53, "from": 1, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033", "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.", "position": 0, "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }